The US Onychomycosis Market Size, Clinical Assessment, Technology, Top Player Analysis Report 2021

The US Onychomycosis Market: Size, Trends & Forecasts (2019-2023 Edition), provides analysis of the US onychomycosis market, with detailed analysis of market size in terms of value, volume and segments. The report also includes the analysis of the larger nail care market in order to showcase the position of onychomycosis with respect to the nail care industry.

Under competitive landscape, different players in the onychomycosis industry have been compared on the basis of parameters such as revenue and market capitalization.

Some of the symptoms of onychomycosis are whitish to yellow-brown discoloration, thickened, distorted in shape, brittle, crumbly or ragged, Smelling slightly foul. Toenail fungal infection can start from foot fungus, and it can spread from one nail to another. Factors that can increase the risk of developing nail fungus include diabetes, circulation problems or a weakened immune system, psoriasis, sweating heavily, reduced blood flow, and more years of exposure to fungi and slower growing nails.

As per some of the Research studies, estimates up to 10% of adults in Western countries have a fungal infection of the nails, and this is projected to increase by 20% in adults who are above 60 years of age. In addition, as per a study published in PLOS PATHOGENS, the prevalence rate of onychomycosis has been reported to be 23% across Europe, and 20% in East Asia. In North America, the incidence of onychomycosis is up to 14%, with fungal infection responsible for 50% of all nail disease.

Increasing the geriatric population, rising prevalence of onychomycosis, and diabetic population worldwide and growing awareness about the potential threats of onychomycosis are the key driving factors in the onychomycosis treatment market.

Avail and Amazing Discount on Report Purchase:

Bausch Health Companies (Formerly Valeant Pharmaceuticals), Pfizer, Inc., Novartis AG and Johnson & Johnson are some of the key players operating in the US onychomycosis market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.

Company Coverage

Bausch Health Companies (Formerly Valeant Pharmaceuticals)
Pfizer, Inc.
Johnson and Johnson
Novartis AG

Executive Summary

Onychomycosis is a condition of fungal nail infection. Onychomycosis begins in the nail bed and progresses to the nail plate, causing the nail to become discolored, deformed, and even separated from the nail bed. Onychomycosis has a significant chance of reoccurrence. Of all the nail abnormalities in the world, around 50% are the case of onychomycosis. In most of the cases it occurs in the toenails. Onychomycosis is not a life threatening disease but, may persist or worsen if not treated.

Symptoms of onychomycosis are changes in appearance of the nail, interference with standing, walking, and exercising, pain, discomfort, etc. The causative pathogens of onychomycosis include dermatophytes (most common), Candida, and nondermatophytic molds.

There are five types of Onychomycosis: Distal Subungual Onychomycosis, White superficial onychomycosis, Proximal subungual onychomycosis, Endonyx onychomycosis and Candidal onychomycosis. Two types of treatments are available of onychomycosis: Oral Treatment and Topical Treatment. Oral treatment includes: Terbinafine, Itraconazole, etc. and topical treatment includes Kerydin, Jublia, etc. Nonpharmacologic approaches are also there, which includes the following: Laser treatment, Photodynamic therapy, etc.

The US onychomycosis market is forecasted to grow at a healthy growth rate during the forecast period (2019-2023). The US onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.

Request for Free Sample@


4. The US Market Analysis

4.1 The US Nail Care Market: An Analysis

4.1.1 The US Nail Care Market by Value
4.1.2 The US Nail Care Market by Segments Segment (Onychomycosis (Antifungal Medications and Non Pharmacological Products) and Other Nail Care Products)

4.2 The US Onychomycosis Market: An Analysis
4.2.1 The US Onychomycosis Market by Value

4.3 The US Onychomycosis Market: Type of Treatment Analysis

4.3.1 The US Onychomycosis Market by Type of Treatment (Pharmacological and Non Pharmacological)
4.3.2 The US Pharmacological Onychomycosis Market by Value
4.3.3 The US Pharmacological Onychomycosis Market by Route of Administration
4.3.4 The US Topical Onychomycosis Market by Value
4.3.5 The US Oral Onychomycosis Market by Value

4.4 The US Onychomycosis Market: Drug Availability Analysis
4.4.1 The US Pharmacological Onychomycosis Market by Drug Availability


About Market Insights Reports

Sales Head: Mr. Irfan Tamboli

+1 (704) 266-3234

Back to top button